A Phase II Multicenter, Open-Label, Single Arm Study to Determine the Efficacy, Safety and Tolerability of AZD2811 and Durvalumab Combination as Maintenance Therapy After Induction with Platinum-Based Chemotherapy Combined with Durvalumab, for the First-Line Treatment of Patients with Extensive Stage Small-Cell Lung Cancer

First-line patients with extensive disease small-cell lung cancer (SCLC)

Maintenance participants alive and progression free (APF12)

Maintenance participants alive at 12 months (OS12), 15 months (OS15), and 18 months (OS18), Maintenance participants alive and progression free at 6 months (APF6) and 9 months (APF9) using investigator assessments according to RECIST 1.1, Objective response rate (ORR) for all participants using investigator assessments according to RECIST 1.1, Maintenance participants Progression-free survival (PFS) using investigator assessments according to RECIST 1.1, Overall survival (OS) in maintenance participants, The safety and tolerability profile of study intervention in SCLC, The pharmacokinetics of durvalumab and AZD2811, Disease-related symptoms & Health-related QoL measured by EORTC QLQ-LC30 & EORTC QLQ-LC13

No related papers found yet.

Spain